002644.SZ
Lanzhou Foci Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 7.45
−0.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 911.0M | 915.5M | 980.2M | 1.2B | 1.0B |
| Cost of Revenue | 594.4M | 603.4M | 680.5M | 801.8M | 737.2M |
| Gross Profit | 316.6M | 312.1M | 299.7M | 361.3M | 305.2M |
| Operating Expenses | |||||
| R&D Expense | 21.6M | 24.6M | 29.3M | 30.9M | 23.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 74.2M | 72.9M | 69.0M | 84.3M | 67.6M |
| Selling & Marketing Expense | 107.6M | 102.4M | 116.0M | 153.7M | 114.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 212.8M | 210.4M | 223.2M | 277.3M | 213.0M |
| Cost and Expenses | 807.2M | 813.9M | 903.7M | 1.1B | 950.2M |
| Operating Income (EBIT) | 70.2M | 66.0M | 70.4M | 83.3M | 143.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 68.3M | 65.0M | 69.1M | 81.6M | 130.7M |
| Income Tax Expense | 18.6M | 18.1M | 7.5M | 13.5M | 21.4M |
| Bottom Line | |||||
| Net Income | 52.5M | 49.2M | 60.1M | 67.2M | 108.7M |
| Earnings from Cont. Ops | 49.7M | 47.0M | 61.7M | 68.1M | 109.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 52.5M | 49.2M | 60.1M | 67.2M | 108.7M |
| Per Share | |||||
| Basic EPS | CN¥0.10 | CN¥0.10 | CN¥0.12 | CN¥0.13 | CN¥0.21 |
| Diluted EPS | CN¥0.10 | CN¥0.10 | CN¥0.12 | CN¥0.13 | CN¥0.21 |
| Revenue Per Share | CN¥1.78 | CN¥1.79 | CN¥1.92 | CN¥2.28 | CN¥2.04 |
| Shares | |||||
| Basic Shares Outstanding | 510.4M | 510.4M | 510.8M | 510.6M | 510.6M |
| Diluted Shares Outstanding | 510.4M | 510.4M | 510.8M | 510.6M | 510.6M |
| Profitability Metrics | |||||
| EBITDA | — | 123.7M | 124.7M | 140.6M | 195.7M |
| D&A | — | 57.7M | 54.3M | 57.4M | 52.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026